Scheme of Amalgamation
Related Links
- NSE Approval of Scheme of ArrangementPDF | 2MB
- BSE Approval of Scheme of ArrangementPDF | 2MB
- Minutes of the Equity Shareholders MeetingPDF | 557KB
- Minutes of Unsecured Creditors MeetingPDF | 521KB
- Attendance Slip - Unsecured Creditors MeetingPDF | 2MB
- Attendance Slip - Equity Shareholders MeetingPDF | 3MB
- Notice for Unsecured Creditors MeetingPDF | 5MB
- Notice for Equity Shareholders MeetingPDF | 16MB
- NCLT Order for conducting MeetingsPDF | 426KB
- Observation Letter - BSEPDF | 166KB
- Observation Letter - NSEPDF | 295KB
- Compliance ReportPDF | 493KB
- Underaking Para 9(a) & (b) of SEBI Circular on Scheme of ArrangementPDF | 749KB
- Auditor CertificatePDF | 1011KB
- Financial details of last three years of Transferee Company and Transferor CompanyPDF | 478KB
- Fairness OpinionPDF | 2MB
- Audit Committee ReportPDF | 850KB
- Valuation ReportPDF | 371KB
- Draft Scheme of AmalgamationPDF | 731KB
- Pre and Post Shareholding Pattern of the Transferee and Transferor CompanyPDF | 5MB
13-12-2018: The Scheme of Amalgamation between the Company and GlaxoSmithKline Consumer Healthcare Limited (GSK CH), and their respective shareholders and creditors, pursuant to the provisions of Sections 230 to 232 and other applicable provisions of Companies Act, 2013, approved by the Board of Directors in their meeting held on 3rd December, 2018 has been submitted with National Stock Exchange of India Limited and BSE Limited.